Pherecydes Pharma

Pherecydes Pharma Overview

Founded 2006
Founded
Status Private
Employees 12
Employees
Latest Deal Type Grant
Latest Deal Amount $2.99M
Latest Deal Amount
Investors 11

Pherecydes Pharma General Information

Description

Developer of therapeutic biotechnologies intended to treat bacterial infections. The company's biotechnologies develops bacteriophages against infections, evaluate phage therapy on infected burn wounds, recognize bacterial target attached to its outer membrane, inject genetic material and reproduce in the host to make new phages that get out and repeat the same cycle, enabling doctors to detect and treat people and their environment against a large range of biothreat agents, including multi-resistant, emergent or previously uncharacterized bacteria.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 22, Boulevard Bénoni Goullin
  • 44200 Nantes
  • France
+33 02 00 00 00 00

Pherecydes Pharma Timeline

2017201820192020
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Pherecydes Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Grant 01-Feb-2018 $2.99M 000.00 Completed Generating Revenue
5. Later Stage VC (Series B) 16-Jan-2018 000.00 000.00 Completed Generating Revenue
4. Later Stage VC (Series A) 18-Mar-2015 00.000 00.000 Completed Generating Revenue
3. Grant 18-Jan-2012 00.000 00.000 Completed Startup
2. Angel (individual) 01-Jan-2007 $3.03M $3.03M Completed Startup
1. Accelerator/Incubator Completed Startup

Pherecydes Pharma Competitors (15)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing
Amount
Vedanta Biosciences Venture Capital-Backed Cambridge, MA 00 00000 0000000000 00000
00000 Formerly VC-backed Ness Ziona, Israel 00 00000 00000000000 00000
00000000 Angel-Backed Boston, MA 0 00.000 0000000000 00.000
00000000 Venture Capital-Backed Cambridge, MA 0 000.00 00000000000 000.00
00 00000000 Private Debt Financed Paris, France 00 000.00 000000000 000.00

Pherecydes Pharma Executive Team (6)

Name Title Board Seat Contact Info
Guy-Charles de La Horie Chief Executive Officer
Jérôme Gabard Ph.D Co-Founder & Chief Operating Officer
Patrick Champion-Arnaud Ph.D Chief Marketing Officer
Cindy Fevre Ph.D Chief Scientific Officer

2 Former Executives

Pherecydes Pharma Board Members (5)

Name Representing Role Since
Claire Poulard Omnes Capital Supervisory Board Member 000 0000
Didier Hoch Self Chairman 000 0000
Emmanuelle Coutanceau Ph.D Auriga Partners (Paris) Board Member 000 0000
Franck Lescure Ph.D Auriga Partners (Paris) Supervisory Board Member 000 0000
Leila Guerlain Nicolas GO Capital (France) Supervisory Board Member 000 0000

Pherecydes Pharma Investors (11)

To view Pherecydes Pharma‘s full investor history, request access »
Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Horizon 2020 Government 000 0000 000000 0
Elaia Partners Venture Capital Minority 000 0000 000000 0
FaDiese Venture Capital Minority 000 0000 000000 0
GO Capital (France) Venture Capital Minority 000 0000 000000 0
Omnes Capital PE/Buyout Minority 000 0000 000000 0

Ready to get started?

Request a free trial